Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
Millions of stroke survivors across the world may soon have a new defense
Merck will showcase results in innovative solutions in HIV treatment and prevention
Subscribe To Our Newsletter & Stay Updated
